Jesse Freeman, 71, suffered a major heart attack at home Had surgery to repair a blocked artery and to insert a stent to keep it open He was then asked to take part in a new study into the use of stem cells These are 'master cells' which can turn into almost any other type of cell in the body, replacing damaged cells He had bone marrow removed from his hip and infused into his heart It is hoped this will regenerate to help heal his damaged heart

By Emma Innes

PUBLISHED: 08:36 EST, 3 March 2014 | UPDATED: 09:55 EST, 4 March 2014

A British man has become the second patient in a Europe to have pioneering stem cell treatment in a bid to prolong his life.

Jesse Freeman, 71, was invited to take part in the landmark trial after suffering a major heart attack at home.

Cardiologists repaired a blocked artery and inserted a stent to keep it open after he was rushed to hospital.

Jesse Freeman (pictured with his wife, Christine) has become the second person in Europe to have pioneering stem cell treatment after a heart attack. It is hoped the procedure will cause his damaged heart muscle to regenerate and that it could eventually become common practice in the treatment of heart attack patients

But while recovering in hospital, he was asked to take part in the major new study to see if heart attack patients can benefit from being treated with their own stem cells.

These are 'master cells' which can turn into almost any other type of cell in the body, replacing damaged cells.

Doctors at the London Chest Hospital, in Bethnal Green, removed bone marrow from Mr Freeman, a grandfather, without general anaesthetic and the cells were then infused into his heart.

More here:
Is this the heart attack treatment of the future? British grandfather has stem cells taken from his hip and injected ...

Recommendation and review posted by Bethany Smith

Current ratings for: Reconstructing faces using human stem cells from fat

Public / Patient:

5 3 ratings

Health Professionals:

0 0 ratings

Researchers in London, UK, are investigating the effectiveness of stem cell therapies for facial reconstruction.

A joint team, from London's Great Ormond Street Hospital for Children and University College London's Institute of Child Health, has published the findings of their research in the journal Nanomedicine.

This follows the recent news that another UK-based team, of The London Chest Hospital, has begun the largest ever trial of adult stem cells in heart attack patients.

Great Ormond Street has a proven track record in facial reconstruction, particularly with regard to treating children with a missing or malformed ear - a condition called microtia. This kind of reconstructive surgery involves taking cartilage from the patient's ribs to craft a "scaffold" for an ear, which is then implanted beneath the skin.

Despite successes with this method, the researchers thought the treatment may be improved by bringing stem cells into the process.

Read more:
Reconstructing faces using human stem cells from fat

Recommendation and review posted by Bethany Smith

Vancouver, BC (PRWEB) March 03, 2014

What if you could discover all the benefits of a chemical peel and microdermabrasion treatment using natural and organic skin care? This spring, minence Organic Skin Care is thrilled to introduce the Arctic Berry Illuminating Collection, a new 3-step peel and peptide system to help you transform your skin and reveal your radiance naturally. Begin with an active exfoliation using papaya enzyme and ground wild cherry bark, followed by an activating peel created with naturally-derived acids from flowers and sugar. Then apply a soothing and revitalizing moisturizer with the illuminating and collagen-boosting power of hibiscus seed botanical peptides, yellow plum, and gardenia stem cells. An exquisite blend of arctic berries, lingonberry seed oil and hibiscus seed extract forms the base of all three products for an active renewing and resurfacing system that is safe for all skin types, including sensitive, rosacea and acne-prone skin.

Peels boast amazing transformation of the skins appearance but most of them contain harsh synthetic chemicals that can actually have damaging effects on the skin, says Boldijarre Koronczay, President of minence Organic Skin Care. We have formulated an all-natural peel that offers our customers the amazing results that they are looking for while being an effective and safe choice.

The following products are included in the Arctic Berry Illuminating System (suggested retail price, $130):

Step 1: Arctic Berry Enzyme Exfoliant Enzymatic and manual exfoliator for all skin types.

Step 2: Arctic Berry Advanced Peel Activator MA10 Multi-acid 10% peel activator for all skin types.

Step 3: Arctic Berry Peptide Radiance Cream Soothing peptide cream for all skin types.

Use the Arctic Berry Peel & Peptide Illuminating System and see incredible results*:

The Arctic Berry Peptide Radiance Cream can be purchased separately as a daily anti-aging and illuminating moisturizer (suggested retail price, $90). The Arctic Berry Peptide Radiance Cream alone is clinically proven to dramatically improve the appearance of fine lines and wrinkles, increase collagen production and decrease wrinkle depth.

Professional treatments are also available at select spas across North America. Visit http://www.eminenceorganics.com to locate a spa near you.

See the article here:
Eminence Organic Skin Care Introduces Transformative Peel and Peptide System

Recommendation and review posted by Bethany Smith

Then they fashion the shape of a nose or an ear by hand, before placing this 'scaffold under the skin of a patient.

However, using the new technique, doctors would simply be able to 'grow a new ear or nose from scratch that would ultimately be biologically indistinguishable from the real thing.

To achieve the breakthrough, researchers took stem cells from a childs abdominal fat and then combined them with a polymer 'nano-scaffold almost a microscopic netting.

They then managed to manipulate this composite in a laboratory so that human cartilage tissue grew into the tiny holes within the polymer.

The technique could now be used to help treat a number of conditions. For patients with 'microtia for example, the stem cells that make the cartilage tissue could be placed in a mould so that it grew into the shape of an ear.

This 'cartilage ear frame would then be inserted under a flap of skin on a patients head which would mould around the shape. When a biodegradable polymer scaffold is used, it would dissolve over time, leaving only human cartilage present.

Although it would not help with other functions, such as hearing, the ear would be biologically indistinguishable from a real outer ear.

A paper on the new technique has now been published in the Journal Nanomedicine: Nanotechnology, Biology and Medicine. Neil Bulstrode, Consultant Plastic Surgeon, at Great Ormond Street Hospital, one of the authors of the research, said: It is such an exciting prospect with regard to the future treatment of these patients and many more.

Currently I take the rib cartilage from the chest to make an ear. I carve a framework in the shape of an ear. Then I will place that framework in a pocket under the skin, which is sucked down with a vacuum so that the skin conforms to the contours of the ear framework.

But if we could produce a block of cartilage using stem cells and tissue engineering, this would be the Holy Grail for our field.

Read the rest here:
Ears and noses could be grown in lab

Recommendation and review posted by Bethany Smith

Experience and expertise run in the genes of this doctor, a third-generation fresh cell therapy practitioner

It was a pleaseant, winter morning in Edenkoben, Germany and a group of 15 people from various countries such as Indonesia, the Philippines, Italy, and Germany congregated for breakfast in a coffee shop in this quaint city. Most of these people just flew in from their respective countries, or drove in from different European cities.

But they were not there for an international conference. They were all there for their shots of fresh cell from Dr. Robert Janson-Mueller.

For the past couple of years, through his solo practice, Dr. Robert Mueller has been sharing the benefits of fresh cell therapy with people who need to seek alternative means to remedy various diseases or chronic conditions of their body, or anti-aging solutions.

Although Filipinos has heard of stem cell therapy only in recent years, thanks to celebrities and politicians who have undergone the treatment and do swear by its efficacy, fresh cell therapy has been around since the 1930s.

The Swiss doctor Prof. Paul Niehans first injected cells originating from animal organs intramuscular into patients in 1931 and is thus considered the founder of live cell therapy. Dr. Robert Muellers grandfather, Dr. Philipp Janson, was one of the first doctors to introduce this method in Germany in 1949. His father, Dr. Wolfgang Janson-Meller, also extensively practiced for 35 years.

Since the 90s, I have been able to participate in the wealth of experience that my father, who is always available for help and advice, has gladly passed on to me. I have been using this method of treatment in my own practice since 2003, says Dr. Mueller.

However, the 47-year old doctor differentiates his practice from others (there are only five known doctors who do fresh cell therapy in Germany) because his clinic tailor-fits the fresh cell injections according to the specific needs of the individuals body. A patient thus gets from about eight to 30 injections, depending on the needs.

In this interview with Dr. Mueller, the German expert sheds more light on this therapy that is attracting more and more Filipinos as an alternative treatment. He also explains why fresh cell therapy is not a cure-all or a miracle therapy, why cells from the sheep embryo is being used, why the treatment is becoming popular in Asia, and why it is not possible, up to now, that these therapies can be done in the Philippines.

For more information on fresh cell therapy, visit the website http://www.janson-mueller.de or call Joey Santos at 0917898-6564 or 633-8653.

See the original post:
Cracking the fresh cell code

Recommendation and review posted by Bethany Smith

The synergy demonstrated between SNS01-T and current standard-of-care drugs further emphasizes the therapeutic potential of SNS01-T. We are excited by these results since there may be utility for SNS01-T-like therapeutics in a range of human malignancies by making simple changes to customize our drug candidate for particular cancer types, stated Professor John Thompson, Ph.D., Chief Scientific Officer of Senesco. Particularly striking is the observation that cancer cells take up more SNS01-T than normal cells and that the malignant cells are also more sensitive to the drug.

SNS01-T was taken up by a series of B-cell tumor cell lines, including multiple myeloma, where uptake was up to 5-fold higher than uptake by normal nave B cells. Uptake into myeloma cells induced ~ 45% cell death within 24 hours, whereas there was almost no measureable death of normal nave B cells. Treatment with SNS01-T resulted in significant dose-dependent inhibition of tumor growth in animal models of multiple myeloma, mantle cell lymphoma and diffuse large B-cell lymphoma, with up to 85-90% inhibition at the highest doses. SNS01-T at 0.18 mg/kg significantly extended the life span of treated mice. There was also a reduction in the pro-survival form of the eIF5A protein in tumor tissue, consistent with drug activity. Finally, the combination of SNS01-T and lenalidomide (the active component of Revlimid) resulted in 100% survival of mice compared to 60% (SNS01-T) and 20% (lenalidomide) survival for either drug alone. Tumors were eradicated after a single 6-week cycle of the combination in 67% of the animals, and there was no regrowth after an additional 8 weeks without further treatment. Similarly, the combination of SNS01-T and bortezomib (the active component of Velcade) inhibited tumor growth by 89% compared to 59% (SNS01-T) and 39% (bortezomib) for either drug alone.

We are pleased that the manuscript from Professor Thompsons lab at the University of Waterloo has been published by Molecular Therapy, stated Dr. Leslie J. Browne, President & CEO of Senesco. Our work at Waterloo in cancer models provides evidence that SNS01-T could become a viable treatment strategy for multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma and other B-cell cancers.

About Senesco Technologies, Inc.

Senesco Technologies is a clinical-stage biotech company specializing in cancer therapeutics. Its proprietary gene regulation technology has demonstrated the ability to eliminate cancer cells and protect healthy cells from premature death. The Company is currently in a Phase 1b/2a trial with a product candidate that is designed to treat B-cell cancers, which include multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkins B-cell lymphomas. The technology was developed over the last 15 years through the discovery that the genetic pathway for cell growth control is common to both plants and humans. For more information, please visit Senesco.com or connect with us on Facebook, Twitter, LinkedIn and Google+.

About SNS01-T

SNS01-T is a novel approach to cancer therapy that is designed to selectively trigger apoptosis in B-cell cancers such as multiple myeloma, and, mantle cell and diffuse large B-cell lymphomas. Senesco is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, MN, the University of Arkansas for Medical Sciences in Little Rock, AK, the Mary Babb Randolph Cancer Center in Morgantown, WV, the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, NJ and the Seattle Cancer Care Alliance in Seattle, WA. http://www.clinicaltrials.gov/ct2/show/NCT01435720?term=SNS01-T&rank=1

Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Companys ability to continue as a going concern; the Companys ability to recruit patients for its clinical trial; the ability of the Company to consummate additional financings; the development of the Companys gene technology; the approval of the Companys patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Companys ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Companys research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Companys products; the timing and success of the Companys preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance, the quotation of the Companys common stock on an over-the-counter securities market, the Companys ability to execute a transaction with Fabrus, Inc., as well as other factors expressed from time to time in the Companys periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Companys periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Visit link:
In Non-clinical Cancer Studies Senescos Therapeutic Candidate, SNS01-T, Works Synergistically in Combination with the ...

Recommendation and review posted by Bethany Smith

Cancer is the second most common cause of death in Switzerland. There are many reasons why in the era of cutting-edge medicine it is still difficult to cure this disease. A tumor may, for instance, consist of different tumor cell subpopulations, each of which has its own profile and responds differently to therapy -- or not. Furthermore, the cancer cells and the healthy cells in the body interact and communicate with one another. How a tumor then actually develops and whether metastases form depends on which signals a tumor cell receives from its environment.

With the development of a new method the team around Prof. Bernd Bodenmiller from the Institute of Molecular Life Sciences at the University of Zurich -- in cooperation with ETH Zurich and University Hospital Zurich -- has succeeded in comprehensively profiling and visualizing tumor cells from patient samples. This promising method has now been published in Nature Methods.

New imaging method -- major opportunity

Setting out to determine a tumor's cell profile, its neighborhood relationships and the circuit structure within and in between cells is a highly complex endeavour. This is because the biomarkers, i.e. the specific molecules of the various cell types and their circuits, have to be measured in their spatial relationships. "With our method it is possible to obtain a comprehensive picture using a novel imaging technique that currently can simultaneously record 32, and in the near future more than one hundred biomarkers," explains Bernd Bodenmiller, the study coordinator. Furthermore, thanks to state-of-the-art imaging the information about the cells' neighborhood relationships is kept and their direct impact on the cellular switch and control circuits can be visualized.

The new technique is based on methods which are already routinely used in hospitals -- with two important innovations. First, the biomarkers are visualized using pure metal isotopes instead of dyes. To do so, biomarkers on very thin tissue sections are labelled with antibodies. The antibodies are coupled to the pure metal isotopes. Then tiny pieces of tissue are removed with a laser system developed by Prof. Detlef Gnther from the ETH Zurich, and the metal isotopes of the pieces are measured with a mass spectrometer which can determine the mass and quantity of the individual metal isotopes. "This trick gets round the problem of the limited number of colours in the analysis of biological samples," comments Bodenmiller.

Secondly, information about the cells, and their control circuits, is no longer qualitative. With the new measurement method it is possible to precisely determine which cells experience what effect and to which extent. In this way the weak points of the control system can be pinpointed and this helps in the development of new therapeutic approaches. This is the reason, so Bodenmiller, why it is becoming increasingly important to understand these interactions for diagnosis and therapy.

Customized treatment is the goal

The initial measurement results of the new biomarker technique for breast cancer have revealed the heterogeneity of tumors. As a consequence of major growth, some tumors suffer from oxygen deficiency on the inside, other misuse the body's own immune cells to drive their growth. Cell-cell interaction and cell location in the centre or on the edges of the tumor also have a decisive influence. One thing is clear: no tumor is like any other and Bodenmiller believes that treatment should reflect this. In a next step his research team wishes to use the new measurement method to explore the roles played by control circuits and cell communication in metastasis formation.

Story Source:

The above story is based on materials provided by University of Zurich. Note: Materials may be edited for content and length.

Read more from the original source:
Homing in on cancer with new imaging method

Recommendation and review posted by Bethany Smith

Scientists have identified a rare gene mutation that prevents Type 2 diabetes, the New York Times reported.

In a study of 150,000 people, researchers identified a mutation that destroys a gene used by pancreas cells where insulin is made. People with the mutation were found to produce slightly higher levels of insulin and have slightly lower blood glucose levels for life. As a result, that the mutation reduces diabetes risk by two-thirds even among people who are overweight.

The results, published in Nature Genetics, are a first for diabetes research, as they show a benefit of a mutation that destroys a gene.

Researchers hope they may someday be able to develop a drug that mimics the mutation, offering protection against diabetes. However, Pfizer, which helped finance the study, cautions that bringing a new drug to market can take 10 to 20 years.

Scientists say these results are surprising and a powerful step for drug development.

The study is a tour de force, and the authors are the top people in the field, Dr. Samuel Klein, director of the center for human nutrition at Washington University School of Medicine, who was not involved in the study, told The New York Times.

Click for more from The New York Times.

Continued here:
Gene mutation may prevent Type 2 diabetes

Recommendation and review posted by Bethany Smith

Current ratings for: Genetic mutations discovered that could prevent type 2 diabetes

Public / Patient:

3.4 5 ratings

Health Professionals:

5 1 rating

Almost 26 million children and adults in the US have diabetes, while 79 million of us have pre-diabetes. Now, researchers have identified rare mutations in a gene that they say could prevent type 2 diabetes - the most common form of the disease - even in people who have risk factors for the condition.

The international research team, led by investigators from the Broad Institute of the Massachusetts Institute of Technology and Harvard, and the Massachusetts General Hospital, recently published the findings in the journal Nature Genetics.

The researchers say that if a drug can be created that mimics the protective effects of these mutations, this could open the doors to the prevention of type 2 diabetes.

To reach their findings, the investigators analyzed the genes of 150,000 individuals over five ancestry groups using next-generation sequencing.

All participants had severe risk factors for diabetes, including advanced age and obesity. However, none of the subjects had developed the condition and had normal blood sugar levels.

Continued here:
Genetic mutations discovered that could prevent type 2 diabetes

Recommendation and review posted by Bethany Smith

Genetic engineering talk show

By: Victor Rodriguez

See the original post:
Genetic engineering talk show - Video

Recommendation and review posted by Bethany Smith

What many didnt realise was that the freaky looking ear was never grown, had nothing to do with genetic engineering and wasnt really a scientific breakthrough at all! Instead, it served as the publics introduction to the new field of tissue engineering, through which researchers attempt to create replacement tissues in the laboratory by combining resorbable materials with stem cells.

Tissue engineers, like those in my laboratory at Kings College London, work to build everything from cartilage to fix creaky arthritic knees to coronary arteries to patch up heart patients. What looked like a human ear grown on a mouse was simply what we call a scaffold, an implantable 3D structure made of a plastic that safely dissolves in the body.

Twenty years later, a UCL-based team led by Dr Patrizia Ferretti is continuing to build on this work to reconstruct ears. Surgeons currently treat microtia, a condition in which children are born with a malformed or missing ear, by taking cartilage from the patients rib and implanting it in the head to form something that looks like an ear.

Dr Ferretti hopes to eliminate the need for this second cartilage-harvesting surgery by growing ear cartilage in the laboratory.

The difference here is that whereas in the 1990s tissue engineers thought that merely forming a scaffold of the correct shape and size would allow us to create a tissue, we now understand that a stem cells perception of its nano-environment plays an important role in determining the tissue it creates.

In short, we can now tailor a scaffold with nano-cues that tell a stem cell to become a liver cell instead of lung.

Dr Ferrettis scaffold does just this. Her team utilises a new nanocaged POSS-PCU scaffold to coax stem cells collected from fat to form cartilage whilst the scaffold slowly melts away.

This exciting material came to light in 2011 when it was used to replace the windpipe of a patient who had to have his own removed because of cancer.

The scaffold here instructed stem cells to create the windpipes lining, essentially using the body as an incubator to help direct their fate. This time, the UCL team utilised a cocktail of chemicals to help push the stem cells to make cartilage, so it remains to be seen if the scaffold will similarly drive ear cartilage formation once placed in the body.

What is clear, however, is that the field of tissue engineering is progressing at a remarkable pace and tailor-made tissues to treat a range of conditions are a real possibility in the near future."

See original here:
Commentary: field of tissue engineering is progressing at remarkable pace

Recommendation and review posted by Bethany Smith

Westport, CT - infoZine - E/The Environmental Magazine - "Synthetic biology" (or "synbio") refers to the design and fabrication of novel biological parts, devices and systems that do not otherwise occur in nature. Many see it as an extreme version of genetic engineering (GE). But unlike GE, whereby genetic information with certain desirable traits is inserted from one organism into another, synbio uses computers and chemicals to create entirely new organisms.

Proponents of synbio, which include familiar players such as Cargill, BP, Chevron and Du Pont, tout its potential benefits. According to the Synthetic Biology Engineering Research Center (SYNBERC), a consortium of leading U.S. researchers in the field, some promising applications of synthetic biology include alternatives to rubber for tires, tumor-seeking microbes for treating cancer, and photosynthetic energy systems. Other potential applications include using synbio to detect and remove environmental contaminants, monitor and respond to disease and develop new drugs and vaccines.

"This is the first major use of a synbio ingredient in food, and dozens of other flavors and food additives are in the pipeline, so synbio vanilla could set a dangerous precedent for synthetic genetically engineered ingredients to sneak into our food supply and be labeled as natural," reports Friends of the Earth (FoE), a leading environmental group. "Synthetic biology vanillin poses several human health, environmental and economic concerns for consumers, food companies and other stakeholders."

For example, FoE worries that synbio vanilla (and eventually other synthetic biology additives) could exacerbate rainforest destruction while harming sustainable farmers and poor communities around the world. "Synbio vanillacould displace the demand for the natural vanilla market," reports FoE. "Without the natural vanilla market adding economic value to the rainforest in these regions, these last standing rainforests will not be protected from competing agricultural markets such as soy, palm oil and sugar." Critics of synbio also worry that releasing synthetic life into the environment, whether done intentionally or accidentally, could have adverse effects on our ecosystems.

Despite these risks, could the rewards of embracing synthetic biology be great? Could it help us deal with some of the tough issues of climate change, pollution and world hunger? Given that the genie is already out of the bottle, perhaps only time will tell.

Related Links SYNBERC: http://www.synberc.org FoE: http://www.foe.org Evolva: http://www.evolva.com

Send your environmental questions to: EarthTalk, c/o E - The Environmental Magazine, P.O. Box 5098, Westport, CT 06881;

View post:
EarthTalk: What is Synthetic Biology?

Recommendation and review posted by Bethany Smith

PHILADELPHIA Using new genetic evidence, an international team of scientists led by experts at the Perelman School of Medicine at the University of Pennsylvania and Childrens Hospital of Philadelphia has found that an increased body mass index (BMI) raised the risk for both type 2 diabetes and higher blood pressure. The results add to mounting evidence about the risks of obesity and are of major importance for the obesity pandemic that is affecting the United States where two-thirds of adults are overweight or obese and other countries. According to the findings, published online in The American Journal of Human Genetics, for every 1 kg/m2 increase in BMI equivalent to a 196-pound, 40-year old man of average height gaining seven pounds the risk of developing type 2 diabetes increases by 27 percent. The same rise in BMI also increases blood pressure by 0.7 mmHg.

Our findings provide solid genetic support indicating that a higher body mass index causes a raised risk of type 2 diabetes and high blood pressure, said the studys lead author, Michael V. Holmes, MD, PhD, research assistant professor of Surgery in the division of Transplant at Penn Medicine.

In the new study, the research team used a recently developed statistical tool called Mendelian randomization (MR), which helps researchers identify genes responsible for particular diseases or conditions (such as obesity), independent of potentially confounding factors such as differences in behavior and lifestyle, which can lead to false-positive associations. In this case, the use of MR virtually rules out the possibility that both a high BMI and type 2 diabetes are caused by a third, unidentified factor.

Whether high BMI raises the risk of adverse outcomes is of critical importance given that BMI is modifiable, said Holmes. Now that we know high BMI is indeed a direct cause of type 2 diabetes, we can reinforce to patients the importance of maintaining body mass within established benchmarks.

Results of the new study were based on the assessment of the genotypes for over 34,500 patients from previous studies. In addition to the results on diabetes and blood pressure, Holmes and his colleagues found that an elevated BMI has potentially harmful effects on several blood markers of inflammation. While this could be tied to increased risk for coronary heart disease, the researchers suggest it requires further study.

While this study has strong foundations and implications, there are many more BMI signals emerging, said senior author Brendan Keating, PhD, research assistant professor of Pediatrics and Surgery at Penn Medicine and lead clinical data analyst in the Center for Applied Genomics at The Childrens Hospital of Philadelphia. Future research will likely generate even more useful information about genetics and the associated risks for disease for both physicians and patients.

###

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania(founded in 1765 as the nation's first medical school) and theUniversity of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 16 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $398 million awarded in the 2012 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals byU.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Original post:
Penn Study Results Confirm BMI is a Direct Cause of Type 2 Diabetes and High Blood Pressure

Recommendation and review posted by Bethany Smith

Advanced Genetics | Minecraft | 1.6.4 | A Quick Guide to Start
Get it Here: http://www.minecraftforum.net/topic/1988826-172164-forge-advanced-genetics-mod/ Attack Of The B-Team - http://www.technicpack.net/attack-of-the-...

By: Draaxlp

See the article here:
Advanced Genetics | Minecraft | 1.6.4 | A Quick Guide to Start - Video

Recommendation and review posted by Bethany Smith

Genetics - Why Most Of What I #39;m Going To Tell You Is Wrong: Dr. Thomas Merritt at TEDxLaurentianU
Dr. Thomas Merritt explores the relationship between our place in time and the scientific knowledge scientists have generated and acquired up until that part...

By: TEDx Talks

See the original post:
Genetics - Why Most Of What I'm Going To Tell You Is Wrong: Dr. Thomas Merritt at TEDxLaurentianU - Video

Recommendation and review posted by Bethany Smith

Amsterdam Weed Review - ORANGENESIA (Amnesia Haze X Agent Orange) - Lady Sativa Genetics 2014
visit http://andrew.pyrah.net for more - COMMENT and LIKE if you enjoyed the video and SUBSCRIBE to see my new videos as they are released - it all helps my ...

By: Andrew Pyrah

Read the original post:
Amsterdam Weed Review - ORANGENESIA (Amnesia Haze X Agent Orange) - Lady Sativa Genetics 2014 - Video

Recommendation and review posted by Bethany Smith

The Professor D Burger Show - Genetics
DNA and Genetics Biology Project 2014. Edited by: Rahul Chaliparambil Scripted by: Preston Henning Directed by: Donavan See.

By: Donavan See

Visit link:
The Professor D Burger Show - Genetics - Video

Recommendation and review posted by Bethany Smith

Top Scientists and Mothers Appeal to Congress for Breakthrough Therapy
Note: This video was originally posted here: http://youtu.be/DTZizFZOtQY Health staffers from over 80 Congressional offices together with agency and industry...

By: The Race to Yes

See the rest here:
Top Scientists and Mothers Appeal to Congress for Breakthrough Therapy - Video

Recommendation and review posted by Bethany Smith

See Inside

A decade and a half after a series of tragic setbacks led to critical reevaluations, scientists say gene therapy is ready to enter the clinic

Gene therapy may finally be living up to its early promise. In the past six years the experimental procedure for placing healthy genes wherever they are needed in the body has restored sight in about 40 people with a hereditary form of blindness. Doctors have seen unprecedented results among another 120-plus patients with various cancers of the bloodseveral of whom remain free of malignancy three years after treatment. Researchers have also used gene therapy to enable a few men with hemophilia, a sometimes fatal bleeding disorder, to go longer without dangerous incidents or the need for high doses of clotting drugs.

The positive results are even more impressive considering that the field of gene therapy essentially ground to a halt 15 years ago, following the untimely death of Jesse Gelsinger, a teenager with a rare digestive disorder. Gelsinger's immune system reacted to the gene treatment he received by launching a counterattack of unexpected ferocity that killed him. Gene therapy's preliminary successes in the 1990s, it turns out, had fueled unreasonably high expectations among doctors and researchersand perhaps a bit of hubris.

2014 Scientific American, a Division of Nature America, Inc.

View Mobile Site All Rights Reserved.

Give a 1 year subscription as low as $14.99

Subscribe Now >>

Originally posted here:
Gene Therapy's Second Act

Recommendation and review posted by Bethany Smith

See Inside

Techniques for getting past the immune system are key to safe and effective treatment

Advances in gene therapy over the past 15 years are finally allowing investigators to safely treat a growing number of carefully selected patients with a broad range of defective or missing genes, as reported by Ricki Lewis in the March issue of Scientific American. One of the biggest obstacles researchers have learned to overcome is the immune systems propensity to over-react when thousands of copies of the stripped-down viruses carrying normal genes are injected into the body, mistakenly treating them as foreign invaders.

Lewis describes the problem and various solutions that are being used in detail in her article. This animation, created by Cortical Studios and Cyberfish, demonstrates one technique that scientists now use to circumvent the immune system in the liver.

2014 Scientific American, a Division of Nature America, Inc.

View Mobile Site All Rights Reserved.

Give a 1 year subscription as low as $14.99

Subscribe Now >>

Read this article:
How Gene Therapy Targets Liver Cells [Video]

Recommendation and review posted by Bethany Smith

London (PRWEB UK) 3 March 2014

Researchers at Oxford University have discovered that by replacing a missing gene into the retina, they can prevent cells from degenerating. Scientists hope that early intervention with the surgical treatment will halt progression of the devastating disorder before patients are entirely robbed of their sight. (http://bit.ly/1gOIohJ)

Superintendent Pharmacist at ChemistDirect, Omar El-Gohary, said: A lot of degenerative eye diseases result from faulty genes. Gene therapy is a new development, which uses technology to replace the defective genes with a normal working copy, with a single injection.

It is the first time gene therapy has successfully been applied to the light-sensitive photoreceptors of the retina, the digital camera at the back of the eye.

Results from the preliminary results done by Oxford University researchers has shown that from the first six patients to take part, two men with advanced stages of choroideremia, (a degenerative retinal disease which leads to loss in sight) experienced dramatic improvements to their sight.

A third of diseases which affect the eyes are genetic in origin and scientists are confident the therapy could be adapted to help patients with other illnesses.

El-Gohary added: Factors other than genetics contributing to the development of eye related diseases can be mutations, which can occur with age and trigger macular disease. The treatment is the same; to replace the faulty gene with a functioning one.

There are currently 500,000 people in Britain with age-related degenerative macular disease, with one in 20 people over 65 suffering from the disease. This pioneering technology could make an enormous difference to the lives of thousands. (http://bit.ly/1fhvH1I)

View post:
Chemist Direct discusses Gene therapy that offers hope to thousands of people suffering from degenerative blindness

Recommendation and review posted by Bethany Smith

Avatars of Human Disease: Personalized Modeling for Personalized Medicine
Visit: http://seminars.uctv.tv/) Preclinical models of human disease, first in vivo then in vitro, have been the source of immense progress in medical resea...

By: UCTVSeminars

See the article here:
Avatars of Human Disease: Personalized Modeling for Personalized Medicine - Video

Recommendation and review posted by sam

Best Local Personal Injury Attorney San Francisco
Looking for a Lawyer? Watch Free Legal Advice on How to Obtain Legal Forms, Legal Help Free Legal Aid to Find the BestLocal Attorneys Near You. San Francis...

By: BestLocal San Francisco

See the original post here:
Best Local Personal Injury Attorney San Francisco - Video

Recommendation and review posted by sam

Arkansas Spinal Cord Injury Attorney
Arkansas Spinal Cord Injury Attorney - Call (501)803-8371 to advertise your business here NOW before your competition does! Details To maintain in Thoughts W...

By: PapenCyndi16c15a8a9a

Follow this link:
Arkansas Spinal Cord Injury Attorney - Video

Recommendation and review posted by sam

Arkansas Spinal Cord Injury Law Firm
Arkansas Spinal Cord Injury Law Firm - Call (501)803-8371 to advertise your business here NOW before your competition does! Things To Keep in Brain When Pick...

By: PapenCyndi16c15a8a9a

More:
Arkansas Spinal Cord Injury Law Firm - Video

Recommendation and review posted by sam